Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine

BMC Neuroscience

Volumn 2, Issue , 2001, Pages

  Turchan, Jadwiga ^a   Anderson, Caroline ^a,b   Hauser, Kurt F ^a   Sun, Qinmiao ^a,b   Zhang, Jiayou ^b   Liu, Ying ^a   Wise, Phyllis M ^a   Kruman, Inna ^c   Maragos, William ^a   Mattson, Mark P ^c   Booze, Rosemarie ^a   Nath, Avindra ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GLYCOPROTEIN GP 120; METHAMPHETAMINE; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ARTICLE; CELL SUBPOPULATION; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE; MOLECULAR INTERACTION; NERVE CELL CULTURE; NERVE CELL MEMBRANE POTENTIAL; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY;

EID: 2642560519     PISSN: 14712202     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2202-2-3     Document Type: Article

References (33)

1. CDC (1996) Center for Disease Control and Prevention: Update: Mortality attributable to HIV infection among persons aged 25-44 years - United S tates 1994. MMWR 1996, 45:121-125
2. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, Quinn TC, Vlahov D: Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998, 352:1510-4
3. Grinspoon S, Corcoran C, Miller K, Biller BM, Askari H, Wang E, Hubbard J, Anderson EJ, Basgoz N, Heller HM, Klibanski A: Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting [published erratum appears in J Clin Endocrinol Metab 1997 Oct;82(10):3360]. J Clin Endocrinol Metab 1997, 82:1332-7
4. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel FD, Glauser M, Antunes F, et al: Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:39-44
5. Robertson K, Vaughn B, Kapoor C, Robertson W, Kalkowski J, Fiscus S, Helms R, Hall C: Gender and Neurological Functioning in HIV Infection. Conference on Human Retroviruses and Related Infections 2000, Abstract #297:
6. Concha M, Selnes OA, Vlahov D, Nance-Sproson T, Updike M, Royal W; Palenicek J, McArthur JC: Comparison of neuropsychological performance between AIDS-free injecting drug users and homosexual men. Neuroepidemiology 1997, 16:78-85
7. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC: Variable progression of HIV-associated dementia. Neurology 1998, 50:1814-20
8. Bell JE, Brettle RP, Chiswick A, Simmonds P: HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 1998, 121:2043-52
9. Reyes MG, Faraldi F, Senseng CS, Flowers C, Fariello R: Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol 1991, 82:39-44
10. Ernst T, Chang L, Leonido-Yee M, Speck O: Evidence for longterm neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 2000, 54:1344-1349
11. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson W.R, Shannak K, Deck J, Niznik HB, Kish SJ: Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 1996, 40:428-39
12. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996, 2:699-703
13. Brown GR: The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med 1995, 25:21-37
14. Nath A: Pathobiology of HIV dementia. Sem Neurol 1999, 19:113-128
15. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD: Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 2000, 47:186-194
16. Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M, Mayeux R: Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000, 54:833-837
17. Slooter AJ, Bronzova J, Witteman JC, Van Broeckhoven C, Hofman A, van Duijn CM: Estrogen use and early onset Alzheimer's disease: a population-based study. J Neurol Neurosurg Psychiatry 1999, 67:779-81
18. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S: The effect of estrogen replacement on early Parkinson's disease. Neurology 1999, 52:1417-1421
19. Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR: Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo- controlled, double-blind, pilot study. Psychoneuroendocrinology 1999, 24:657-77
20. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, Geiger JD: Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 1996, 70:1475-1480
21. Nath A, Maragos W, Avison M, Schmitt F, Berger J: Accelerated HIV dementia with methamphetamine and cocaine use. J Neurovirol
22. Hudson L, Liu J, Nath A, Narayan O, Male D, Jones M, Everall I: Detection of human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 2000, 6:145-155
23. Green PS, Simpkins JW: Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000, 18:347-358
24. Gundlah C, Kohama SG, Mirkes SJ, Garyfallou VT, Urbanski HF, Bethea CL: Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Brain Res Mol Brain Res 2000, 76:191-204
25. Zheng J, Ramirez VD: Purification and identification of an estrogen binding protein from rat brain: oligomycin sensitivity-conferring protein (OSCP), a subunit of mitochondrial F0F1-ATP synthase/ATPase. J Steroid Biochem Mol Biol 1999, 68:65-75
26. Gillum LA, Mamidipudi SK, Johnston SC: Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000, 284:72-78
27. Hoffmann M, Berger JR, Nath A, Rayens M: Cerebrovascular disease in young, HIV-infected, black Africans in the KwaZulu Natal province of South Africa. J Neurovirol 2000, 6:229-36
28. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A: Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 1995, 37:373-380
29. Zamboni L, De Martino C: Buffered picric acid formaldehyde: a new rapid fixative for electron microscopy. J.Cell Biol 1967, 35:148A-
30. Nath A, Conant K, Chen P, Scott C, Major EO: Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes : A hit and run phenomenon. J. Biol. Chem 1999, 274:17098-17102
31. Hoshimaru M, Ray J, Sah DW, Gage FH: Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. Proc Natl Acad Sci U S A 1996, 93:1518-1523
32. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-70
33. Ma M, Nath A: Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 1997, 71:2495-2499